



Innovations and Translations in Parkinsonism and Related Disorders

Saturday, 1 May 2021			
Time Zone CET			
15:00	<p>15:00 - 16:30</p> <p>Parallel 1: Biomarkers Chair: Etienne Hirsch (France) and Wilma van de Berg (Netherlands)</p> <p>1a. Biomarkers in biofluids <i>Wilma van de Berg (Netherlands)</i></p> <p>1b. Biomarkers in biotissue <i>Pascal Derkinderen (France)</i></p> <p>1c. Neuroimaging biomarkers <i>Ken Marek (USA)</i></p>	<p>15:00 - 16:30</p> <p>Parallel 2: Technology Based Assessment Chairs: Mark Lew (USA) and Rajesh Pahwa (USA)</p> <p>2a. Digital monitoring tools in Parkinson disease <i>Roongroj Bhidayasiri (Thailand)</i></p> <p>2b. Virtual/clinical telemedicine <i>Anhar Hassan (USA)</i></p> <p>2c. Digital monitoring tools in chorea <i>Joaquim Ferreira (Portugal)</i></p>	<p>15:00 - 16:30</p> <p>Educational Course 1: Parkinsonian Syndromes Chairs: Zbigniew Wszolek (USA) and Kailash Bhatia (UK)</p> <p>1a. Parkinson's and related syndromes: Time to reject the Braak hypothesis <i>Alberto Espay (USA)</i></p> <p>1b. Genetic causes of parkinsonism (genotype/phenotype correlations) <i>Andreas Puschmann (Sweden)</i></p> <p>1c. Etiology and phenomenology of atypical parkinsonian syndromes: diagnosis by observation <i>Kailash Bhatia (UK)</i></p>
16:30	16:30 - 17:00 Break / ePoster visit		
17:00	<p>17:00 - 17:30</p> <p>Opening Ceremony <i>Daniel Truong (USA), Mark Hirsch (USA), Mark Lew (USA), Teus van Laar (NL)</i></p>		
17:30	<p>17:30 - 18:00</p> <p>Kick-off Plenary Lecture: Is Alpha-Synuclein Still the Basis of Parkinson Disease? <i>Etienne Hirsch (France)</i> <i>Patrik Brundin (USA)</i></p>		
18:00	<p>18:00 - 18:30</p> <p>Melvin Yahr Lecture: Parkinson Disease and Essential Tremor: How Are They Related? <i>Daniel Truong (USA)</i> <i>Joseph Jankovic (USA)</i></p>		
18:30	18:30 - 19:00 Break / ePoster visit		
19:00	<p>19:00 - 19:30</p> <p>Lifetime Achievement Award Lecture: Discovering the Genetic Causes of Parkinson Disease <i>Erik Wolters (NL)</i> <i>Zbigniew Wszolek (USA)</i></p>		
19:30	<p>19:30 - 20:30</p> <p>Best of Parkinsonism and Related Disorders and Clinical Parkinsonism and Related Disorders Chairs: Vincenzo Bonifati (Netherlands) and Hubert Fernandez (USA)</p> <p>a. Basic/ translational PRD papers <i>Wasillios Meissner (France)</i></p> <p>b. Clinical PRD papers <i>Janis Miyasaki (Canada)</i></p> <p>c. CPRD papers <i>Huifang Shang (China)</i></p>		
20:00			
20:30			

Sunday, 2 May 2021

Time Zone CET			
15:00	<p>15:00 - 16:30</p> <p>Parallel 3: Gut Brain Axis Debate Chairs: <i>Teus van Laar (NL)</i> and <i>Filip Scheperjans (Finland)</i></p>	<p>15:00 - 16:30</p> <p>Parallel 4: Botulinum Toxins: New Indications in Movement Disorders Chairs: <i>Daniel Truong (USA)</i> and <i>Diego Torres-Russotto (USA)</i></p>	<p>15:00 - 16:30</p> <p>Educational Course 2: Investigations in Movement Disorders Chairs: <i>Mark Hallett (USA)</i> and <i>Ioannis Isaïas (Germany)</i></p>
15:30	<p>3a. Are microbiome changes important? - Yes - <i>Jeffrey Boertien (NL)</i> - No - <i>Petri Auvinen (Finland)</i> - Discussion, Q&A</p>	<p>4a. Spasticity and sialorrhea <i>Erle Lim (Singapore)</i></p>	<p>2a. Imaging <i>Ioannis Isaïas (Germany)</i></p>
16:00	<p>3b. Modifying gut microbiota is a promising treatment for Parkinson's disease. Yes/No - Yes - <i>Fiorella Contarino (NL)</i> - No - <i>Roberto Cilia (Italy)</i> - Discussion, Q&A</p>	<p>4b. Monitoring spread of botulinum toxin with ultrasound <i>Stefan Meng (Austria)</i></p>	<p>2b. Neurophysiology <i>Mark Hallett (USA)</i></p>
16:30	<p>16:30 - 17:00 Break / ePoster visit</p>		
17:00	<p>17:00 - 18:30 Industry Session: Merz Therapeutics</p>		<p>17:00 - 18:30 Industry Session: Sunovion</p>
17:30			
18:00			
18:30	<p>18:30 - 19:00 Break / ePoster visit</p>		
19:00	<p>19:00 - 20:30</p> <p>Parallel 5: Pathophysiology of Parkinsonian Syndromes Chairs: <i>Etienne Hirsch (France)</i> and <i>Erik Wolters (NL)</i></p>	<p>19:00 - 20:30</p> <p>Parallel 6: Surgical Therapies in Movement Disorders Chairs: <i>Marc van Dijk (NL)</i> and <i>Andres Lozano (Canada)</i></p>	<p>19:00 - 20:30</p> <p>Educational Course 3: Translational Treatment in Parkinson Disease Chairs: <i>Mark Hirsch (USA)</i> and <i>Erwin van Wegen (NL)</i></p>
19:30	<p>5a. Role of protein processing and lysosomal function in Parkinson disease <i>Harm Kampinga (NL)</i></p>	<p>6a. Recent progress in neurosurgical treatment of dystonias <i>Taira Takaomi (Japan)</i></p>	<p>3a. Allied health <i>Mark Hirsch (USA)</i></p>
20:00	<p>5b. Role of gut, systemic, and CNS inflammation <i>Kathleen Shannon (USA)</i></p>	<p>6b. Conventional lesioning surgery vs. Focused ultrasound <i>W. Jeffrey Elias (USA)</i>—conventional lesioning <i>Alfosno Fasano (Canada)</i>—focused ultrasound</p>	<p>3b. Pharmacotherapy <i>Yaroslau Compta (Spain)</i></p>
	<p>5c. Environmental factors in Parkinson disease <i>Roel Vermeulen (NL)</i></p>	<p>6c. Advances in movement disorder surgery <i>Andres Lozano (Canada)</i></p>	<p>3c. Deep brain stimulation and focused ultrasound <i>Yasin Temel (NL)</i></p>
20:30			

Monday, 3 May 2021

Time Zone CET			
15:00	<p>15:00 - 16:30</p> <p>Parallel 7: Gene and Cell Based Therapies Chair: Jeffrey Kordower (USA) and Patrik Brundin (USA)</p>	<p>15:00 - 16:30</p> <p>Parallel 8 Debate: Exercise Therapy in Parkinson's Disease Chair: Erwin van Wegen (NL) and Mark Hirsch (USA)</p>	<p>15:00 - 16:30</p> <p>Educational Course 4: Pathophysiology and Treatment in Hyperkinesia Chair: Daniel Truong (USA) and Angela Cenci- Nilsson (Sweden)</p>
15:30	<p>7a. α-Synuclein and Mitochondria Associated Membrane protein Serge Przedborski (USA)</p>	<p>8a. Neurophysiology of exercise in PD (motor and non-motor) Ulrik Dalgas (Denmark)</p>	<p>4a. Tremor Sheng-Han Kuo (USA)</p>
16:00	<p>7b. Synuclein-directed gene or antibody therapy in Parkinson disease Mathias Bähr (Germany)</p> <p>7c. Gene therapy for neurotrophic factors Hideki Mochizuki (Japan)</p>	<p>8b. Physical exercise is neurorestorative in Parkinson's disease: - Yes - Guiseppe Frazzitta (Italy) - No - Mark Stacy (USA) Discussion</p>	<p>4b. Dystonia Cynthia Comella (USA)</p> <p>4c. Myoclonus Ashley Pena (USA)</p>
16:30	16:30 - 16:45 Break / ePoster visit		
17:00	<p>16:45 - 18:15</p> <p>Industry Session: Sunovion</p>		<p>16:45 - 18:15</p> <p>Industry Session: Britannia Pharmaceuticals LTD</p>
17:30			
18:00			
18:15 - 18:30 Break / ePoster visit			
18:30	<p>18:30 - 20:00</p> <p>Plenary 1: Neuropsychiatric Issues in Parkinson Disease Chairs: Rajesh Pahwa (USA) and Iris Sommer (NL)</p>		
19:00	<p>1a. Dementia in Parkinson's disease: features, diagnosis and treatment Murat Emre (Turkey)</p>		
19:30	<p>1b. Depression in PD Annette Schrag (UK)</p> <p>1c. Impulse control disorders in PD Daniel Weintraub (USA)</p>		
20:00	20:00 - 20:15 Break / ePoster visit		
20:30	<p>20:15 - 21:15</p> <p>Grand Parade of Movement Disorders Video Challenge Chairs: Alberto Albanese (Italy), Kailash Bhatia (UK), Susanne Schneider (Germany), Shinsuke Fujioka (Japan), Hubert Fernandez (USA)</p>		
21:00			
21:30			

Tuesday, 4 May 2021

Time Zone CET			
15:00	<p>15:00 - 16:30 Plenary 2: Genetics of Parkinson Disease <i>Chairs: Zbigniew Wszolek (USA) and Eng King Tan (Singapore)</i></p>		
15:30	<p>2a. Monogenetic causes of Parkinson disease <i>Vincenzo Bonifati (NL)</i></p>		
16:00	<p>2b. Genetic variants and susceptibility genes in Parkinson disease <i>Owen Ross (USA)</i></p>		
16:30	<p>2c. GBA and LRRK2: mechanisms for novel Parkinson disease treatments <i>Ziv Gan-Or (Canada)</i></p>		
16:30	<p>16:30 - 17:00 Break / ePoster visit</p>		
17:00	<p>Parallel 9: Translational Therapies in Movement Disorders <i>Chair: Erik Wolters (NL) and Gesine Paul-Visse (Sweden)</i></p>	<p>17:00 - 18:30 Parallel 10: Balance and Gait Disorders: New Therapeutic Interventions <i>Chairs: Erwin van Wegen (NL) and Mark Hirsch (USA)</i></p>	<p>17:00 - 18:30 Parallel 11: Infusion Therapies in Parkinson Disease <i>Chairs: Teus van Laar (NL) and Tove Henriksen (Denmark)</i></p>
17:30	<p>9a. Autologous stem cell therapies <i>Hans de Munter (NL)</i></p>	<p>10a. Update on pathophysiology <i>Jinyoung Youn (Korea)</i></p>	<p>11a. Pros and cons of infusion therapies <i>Peter LeWitt (USA)</i></p>
18:00	<p>9b. Immune response in Parkinson disease: immunomodulation as a future therapeutic strategy <i>Marina Romero-Ramos (Denmark)</i></p>	<p>10b. Virtual reality for gait/gait training in Parkinson disease <i>Monika Pötter-Nerger (Germany)</i></p>	<p>11b. Update on apomorphine infusion <i>Tove Henriksen (Denmark)</i></p>
	<p>9c. Growth factor infusions <i>Gesine Paul-Visse (Sweden)</i></p>	<p>10c. Personalized gait rehabilitation in Parkinson disease <i>Jorik Nonnekes (NL)</i></p>	<p>11c. Motor and non-motor effects of levodopa-carbidopa intestinal gel infusion <i>Per Odin (Sweden)</i></p>
18:30	<p>18:30 - 19:00 Break / ePoster visit</p>		
19:00	<p>19:00 - 20:30 Parallel 12: What's New in Hyperkinetic Disorders? <i>Chairs: Mark Lew (USA) and William Ondo (USA)</i></p>	<p>19:00 - 20:30 Parallel 13: Promising Future Therapies <i>Chairs: Stuart Isaacson (USA) and Daniel Kremens (USA)</i></p>	<p>19:00 - 20:30 Parallel 14: Allied Health Rehabilitation in Parkinson Disease <i>Chair: Erwin van Wegen (NL) and Mark Hirsch (USA)</i></p>
19:30	<p>12a. What's new in HD/chorea? <i>Oksana Suchowersky (Canada)</i></p>	<p>13a. Repurposing strategies to prevent or slow Parkinson disease <i>Michael Schwarzschild (USA)</i></p>	<p>14a. Allied health update on fine motor skills in Parkinson disease <i>Tim Vanbellingen (Switzerland)</i></p>
20:00	<p>12b. What's new in dystonia? <i>Marie Vidailhet (France)</i></p>	<p>13b. Cannabinoids <i>Florin Gandor (Germany)</i></p>	<p>14b. Multi-disciplinary approach to wearing off-related psychiatric symptoms <i>Odile van den Heuvel (NL)</i></p>
	<p>12c. What's new in tremor? <i>Elan Louis (USA)</i></p>	<p>13c. Noninvasive brain stimulation <i>Christian Baumann (Switzerland)</i></p>	
	<p>12d. What's new in tardive dyskinesia? <i>Stanley Caroff (USA)</i></p>		
20:30	<p>20:30 - 20:40 Closing Words IAPRD President Daniel Truong (USA)</p>		
21:00			